Table 3.
Concomitant diseases in HER2-positive patients without adjuvant trastuzumab treatment.
| Premenopausal | Postmenopausal | All patients | |
|---|---|---|---|
| Concomitant diseases, n (%) | 35 (14.8%) | 202 (85.2%) | 237 (100.0%) |
| Cardiopulmonary | 12/35 (34.3%) | 126/202 (62.4%) | 138/237 (58.2%) |
| Gastrointestinal/hepatic/renal | — | 10/202 (5.0%) | 10/237 (4.2%) |
| Metabolic | 7/35 (20.0%) | 22/202 (10.9%) | 29/237 (12.2%) |
| Mental | 6/35 (17.1%) | 15/202 (7.4%) | 21/237 (8.9%) |
| Others | 10/35 (28.6%) | 29/202 (14.4%) | 39/237 (16.5%) |